Lv1
78 积分 2024-02-25 加入
A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review
1个月前
已完结
Myocardial Ischemia-Reperfusion Injury: Therapeutics from a Mitochondria-Centric Perspective
2个月前
已完结
Ginsenoside Re attenuates myocardial ischemia/reperfusion induced ferroptosis via miR-144-3p/SLC7A11
2个月前
已完结
Ginsenoside Rk1 improves mitochondrial function and alleviates myocardial ischemia-reperfusion injury by regulating SIRT3
2个月前
已完结
Ginsenoside Rd promotes cardiac regeneration through PPARG/HMGCS2-driven ketone body metabolic reprogramming in myocardial ischemia-reperfusion injury
2个月前
已完结
Protective Effect of Shexiang Baoxin Pill on Myocardial Ischemia/Reperfusion Injury in Patients With STEMI
2个月前
已完结
A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review
2个月前
已完结
A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review
2个月前
已完结
Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs
2个月前
已完结
Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function
2个月前
已完结
皖公网安备34019202002308
